Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma

Odontology

Volumn 96, Issue 1, 2008, Pages 32-37

  Yamazaki, Yutaka ^a   Chiba, Itsuo ^b   Ishikawa, Makoto ^a   Satoh, Chiharu ^a   Notani, Ken Ichi ^a   Ohiro, Yoichi ^a   Totsuka, Yasunori ^a   Mizuno, Shigeaki ^c   Kitagawa, Yoshimasa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Oral squamous cell carcinoma; P53; P53 antibodies; Prognosis; Serum

Indexed keywords

AUTOANTIBODY; CANCER ANTIBODY; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MOUTH TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; AUTOANTIBODIES; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48449089195     PISSN: 16181247     EISSN: 16181255     Source Type: Journal    
DOI: 10.1007/s10266-008-0079-y     Document Type: Article

References (31)

1. Krimmel M, Hoffman J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC-Ag, CEA, CA19.9 and CA125 for diagnosis and follow-up in oral cancer. Craniomaxillofac Surg 1998;26:243-248.
2. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998;11:35-39.
3. Ashitani J, Mukae H, Ihiboshi H, Taniguchi H, Mashimoto H, Motsukura S. Adult respiratory distress syndrome with increased serum and bronchoalveolar lavage fluid levels of squamous cell carcinoma-related antigen. Intern Med 1996;35:497-501.
4. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balaque A. SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990;36:251-254.
5. Esajas MD, Duk JM, de Bruijn HWA, Aalders JG, Willemse PHB, Sluiter W, Pras B, ten Hoor K, Hollema H, van der Zee AGJ. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001;19:3960-3966.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
7. Soussi T. p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-1788.
8. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, Hayashi H, Takeda A, Ochiai T. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002;132:41-47.
9. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various of malignant tumors. Cancer 2003;97:682-689.
10. Kaur J, Srivastava A, Ralhan R. Serum p53 antibodies in patients with oral lesions: Correlation with p53/HSP70 complexes. Int J Cancer 1997;74:609-613.
11. Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK. Circulating p53 antibodies as early markers of oral cancer: Correlation with p53 alterations. Clin Cancer Res 1998;4:2147-2152.
12. Ralhan R, Agarwal S, Nath N, Mathur M, Wasylyk B, Srivastava A. Correlation between p53 gene mutations and circulating antibodies in betel and tobacco consuming North Indian population. Oral Oncol 2001;37:243-250.
13. Sainger RN, Shah MH, Desai AA, Shukla SN, Shah PM, Telang SD, Patel PS. Clinical significance of serum p53 antibodies in oral cancer. Tumori 2006;92:134-139.
14. Hofele C, Schwager-Schmitt M, Volkmann M. Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma - five years survival rate. Laryngorhinootologie 2002;81:342-345.
15. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed. Geneva, Switzerland: International Union Against Cancer; 1997.
16. Yamamoto E, Kohama G, Sunakawa H, Iwai M, Hiratsuka H. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983;51:2175-2180.
17. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-622.
18. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 1998;77:1848-1851.
19. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, Sugimachi K. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999;85:302-308.
20. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1228-1233.
21. Werner JA, Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD, Rudert H. p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother 1997;44:112-116.
22. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-6384.
23. Lavieille J-P, Righini C, Reyt E, Brambilla C, Riva C. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas. Oral Oncol 1998;34:84-92.
24. Castelli M, Cianfriglia F, Manieri A, Palma L, Pezzuto RW, Falasca G. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Anticancer Res 2001;21:753-758.
25. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-702.
26. Zalcman G, Schlichtholz B, Tredaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A, Soussi T. Monitoring of p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment. Clin Cancer Res 1998;4:1359-1366.
27. Gumus E, Demirel G, Tanriverdi O, Horasanli K, Ozmen G, Miroglu C. Importance of serum p53 antibodies during follow-up after treatment of invasive bladder tumors. Urol Int 2004;72:292-298.
28. Gluckman JL, Crissman JD. Survival rates in 548 patients with multiple neoplasms of the upper aerodigestive tract. Laryngoscope 1983;93:71-74.
29. Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 1999;21:204-210.
30. Takeda A, Shimada H, Nakajima K, Yoshimura S, Suzuki T, Asano T. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol 2001;6:45-49.
31. Wang MH, Li YP, Wang XD, Zhang H, Xiong LH, Huang HZ. Correlation between serum p53 antibody and chemosensitivity in patient with esophageal cancer. Chin J Cancer 2004;23:467-470.